Ulrich Forstermann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11744278/publications.pdf

Version: 2024-02-01

9775 6990 24,580 177 73 154 citations h-index g-index papers 181 181 181 24398 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Regulation of NADPH Oxidase-Mediated Superoxide Production by Acetylation and Deacetylation. Frontiers in Physiology, 2021, 12, 693702.	1.3	2
2	Phosphorylation and activation of endothelial nitric oxide synthase by red fruit (Pandanus conoideus) Tj ETQq0	O 0 rgBT /0	Overlock 10 Tf
3	Red fruit (Pandanus conoideus Lam) oil stimulates nitric oxide production and reduces oxidative stress in endothelial cells. Journal of Functional Foods, 2018, 51, 65-74.	1.6	9
4	Antioxidant effects of resveratrol in the cardiovascular system. British Journal of Pharmacology, 2017, 174, 1633-1646.	2.7	397
5	Restoration of perivascular adipose tissue function in dietâ€induced obese mice without changing bodyweight. British Journal of Pharmacology, 2017, 174, 3443-3453.	2.7	41
6	Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circulation Research, 2017, 120, 713-735.	2.0	962
7	European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biology, 2017, 13, 94-162.	3.9	242
8	Effects of resveratrol on eNOS in the endothelium and the perivascular adipose tissue. Annals of the New York Academy of Sciences, 2017, 1403, 132-141.	1.8	32
9	Uncoupling of eNOS in Cardiovascular Disease. , 2017, , 117-124.		3
10	Estrogen Receptor Signaling and the PI3K/Akt Pathway Are Involved in Betulinic Acid-Induced eNOS Activation. Molecules, 2016, 21, 973.	1.7	25
11	Uncoupling of Endothelial Nitric Oxide Synthase in Perivascular Adipose Tissue of Diet-Induced Obese Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 78-85.	1.1	158
12	Downregulation of BDNF Expression by PKC and by TNF- $\hat{l}\pm$ in Human Endothelial Cells. Pharmacology, 2015, 96, 1-10.	0.9	32
13	Maternal Treatment of Spontaneously Hypertensive Rats With Pentaerythritol Tetranitrate Reduces Blood Pressure in Female Offspring. Hypertension, 2015, 65, 232-237.	1.3	42
14	Nitric Oxide Synthesis in Vascular Physiology and Pathophysiology. , 2015, , 381-397.		3
15	Dexamethasone, tetrahydrobiopterin and uncoupling of endothelial nitric oxide synthase. Journal of Geriatric Cardiology, 2015, 12, 528-39.	0.2	7
16	Resveratrol and Endothelial Nitric Oxide. Molecules, 2014, 19, 16102-16121.	1.7	119
17	Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity. Nucleic Acids Research, 2014, 42, 12555-12569.	6.5	54
18	Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis, 2014, 237, 208-219.	0.4	519

#	Article	IF	CITATIONS
19	Dexamethasone Upregulates Nox1 Expression in Vascular Smooth Muscle Cells. Pharmacology, 2014, 94, 13-20.	0.9	18
20	Artichoke, Cynarin and Cyanidin Downregulate the Expression of Inducible Nitric Oxide Synthase in Human Coronary Smooth Muscle Cells. Molecules, 2014, 19, 3654-3668.	1.7	28
21	Pharmacological Prevention of eNOS Uncoupling. Current Pharmaceutical Design, 2014, 20, 3595-3606.	0.9	56
22	Resveratrol as a Gene Regulator in the Vasculature. Current Pharmaceutical Biotechnology, 2014, 15, 401-408.	0.9	26
23	Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide - Biology and Chemistry, 2013, 32, 29-35.	1.2	125
24	Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Current Opinion in Pharmacology, 2013, 13, 161-167.	1.7	232
25	Oxidative stress in vascular disease and its pharmacological prevention. Trends in Pharmacological Sciences, 2013, 34, 313-319.	4.0	261
26	Paraoxonases-2 and -3 Are Important Defense Enzymes against <i>Pseudomonas aeruginosa</i> Virulence Factors due to Their Anti-Oxidative and Anti-Inflammatory Properties. Journal of Lipids, 2012, 2012, 1-9.	1.9	23
27	Red Wine and Cardiovascular Health. Circulation Research, 2012, 111, 959-961.	2.0	40
28	Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide - Biology and Chemistry, 2012, 26, 102-110.	1.2	250
29	Nitric Oxide: Biological Synthesis and Functions. , 2012, , 1-36.		O
30	Transcriptional regulation of Nox4 by histone deacetylases in human endothelial cells. Basic Research in Cardiology, 2012, 107, 283.	2.5	61
31	Nitric oxide synthases: regulation and function. European Heart Journal, 2012, 33, 829-837.	1.0	3,036
32	Resveratrol und Gesundheit. , 2012, , 199-206.		0
33	Relative contribution of different l-arginine sources to the substrate supply of endothelial nitric oxide synthase. Journal of Molecular and Cellular Cardiology, 2011, 51, 855-861.	0.9	16
34	Betulinic acid protects against cerebral ischemiaâ€"reperfusion injury in mice by reducing oxidative and nitrosative stress. Nitric Oxide - Biology and Chemistry, 2011, 24, 132-138.	1.2	51
35	Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. British Journal of Pharmacology, 2011, 164, 213-223.	2.7	245
36	Paraoxonase 2 is down-regulated by the <i>Pseudomonas aeruginosa</i> quorumsensing signal <i>N</i> -(3-oxododecanoyl)- <scp>L</scp> -homoserine lactone and attenuates oxidative stress induced by pyocyanin. Biochemical Journal, 2010, 426, 73-83.	1.7	54

#	Article	IF	CITATIONS
37	Nitric oxide and oxidative stress in vascular disease. Pflugers Archiv European Journal of Physiology, 2010, 459, 923-939.	1.3	592
38	Uncoupling of Endothelial Nitric Oxide Synthase in Cardiovascular Disease and its Pharmacological Reversal., 2010,, 139-167.		5
39	Resveratrol Reverses Endothelial Nitric-Oxide Synthase Uncoupling in Apolipoprotein E Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 149-154.	1.3	154
40	Pentaerythritol Tetranitrate Improves Angiotensin II–Induced Vascular Dysfunction via Induction of Heme Oxygenase-1. Hypertension, 2010, 55, 897-904.	1.3	66
41	<i>Prunella vulgaris</i> L. Upregulates eNOS Expression in Human Endothelial Cells. The American Journal of Chinese Medicine, 2010, 38, 599-611.	1.5	16
42	One Enzyme, Two Functions. Journal of Biological Chemistry, 2010, 285, 24398-24403.	1.6	136
43	Resveratrol: A Multifunctional Compound Improving Endothelial Function. Cardiovascular Drugs and Therapy, 2009, 23, 425-429.	1.3	37
44	Molecular mechanisms underlying pharmacological stimulation of eNOS expression and eNOS activity. BMC Pharmacology, 2009, 9, .	0.4	0
45	Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects. Physiological Genomics, 2009, 38, 176-185.	1.0	25
46	Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System. Current Pharmaceutical Design, 2009, 15, 3133-3145.	0.9	133
47	Inhibitors of Inducible NO Synthase Expression: Total Synthesis of (<i>S</i>)â€Curvularin and Its Ring Homologues. ChemMedChem, 2008, 3, 924-939.	1.6	33
48	Differential roles of PKCα and PKCÉ> in controlling the gene expression of Nox4 in human endothelial cells. Free Radical Biology and Medicine, 2008, 44, 1656-1667.	1.3	81
49	Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis, 2008, 198, 65-76.	0.4	118
50	Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 338-349.	3.3	471
51	Antiatherosclerotic Effects of Small-Molecular-Weight Compounds Enhancing Endothelial Nitric-Oxide Synthase (eNOS) Expression and Preventing eNOS Uncoupling. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 370-379.	1.3	81
52	Protein kinase C Â promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. Cardiovascular Research, 2008, 78, 349-355.	1.8	83
53	Cyclooxygenase 2-Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs Induce Oxidative Stress by Up-Regulating Vascular NADPH Oxidases. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 745-753.	1.3	55
54	Simultaneous Assessment of Endothelial Function, Nitric Oxide Synthase Activity, Nitric Oxide–Mediated Signaling, and Oxidative Stress in Individuals with and without Hypercholesterolemia. Clinical Chemistry, 2008, 54, 292-300.	1.5	45

#	Article	IF	CITATIONS
55	Protective effect of paraoxonase-2 against endoplasmic reticulum stress-induced apoptosis is lost upon disturbance of calcium homoeostasis. Biochemical Journal, 2008, 416, 395-405.	1.7	51
56	Post-Transcriptional Regulation of Human Inducible Nitric-Oxide Synthase Expression by the Jun N-terminal Kinase. Molecular Pharmacology, 2007, 71, 1427-1434.	1.0	47
57	Deficiency of Glutathione Peroxidase-1 Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 850-857.	1.1	169
58	Paraoxonase-2 Reduces Oxidative Stress in Vascular Cells and Decreases Endoplasmic Reticulum Stress–Induced Caspase Activation. Circulation, 2007, 115, 2055-2064.	1.6	224
59	Heme Oxygenase-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1729-1735.	1.1	84
60	Animal Models of Hypertension. Methods in Molecular Medicine, 2007, 139, 105-111.	0.8	3
61	The untranslated region of exon 2 of the human neuronal nitric oxide synthase (NOS1) gene exerts regulatory activity. Gene, 2007, 405, 36-46.	1.0	9
62	Ursolic acid from the Chinese herb Danshen (Salvia miltiorrhiza L.) upregulates eNOS and downregulates Nox4 expression in human endothelial cells. Atherosclerosis, 2007, 195, e104-e111.	0.4	67
63	Reciprocal Regulation of Endothelial Nitric-Oxide Synthase and NADPH Oxidase by Betulinic Acid in Human Endothelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 836-842.	1.3	67
64	Endothelial Nitric Oxide Synthase., 2007, , 1-8.		1
65	Endothelial Nitric Oxide Synthase in Vascular Disease. Circulation, 2006, 113, 1708-1714.	1.6	1,641
66	Reversal of Endothelial Nitric Oxide Synthase Uncoupling and Up-Regulation of Endothelial Nitric Oxide Synthase Expression Lowers Blood Pressure in Hypertensive Rats. Journal of the American College of Cardiology, 2006, 47, 2536-2544.	1.2	163
67	Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biological Chemistry, 2006, 387, 1521-33.	1.2	134
68	Transcription of human neuronal nitric oxide synthase mRNAs derived from different first exons is partly controlled by exon 1-specific promoter sequences. Genomics, 2006, 87, 463-473.	1.3	41
69	Endothelial NO synthase as a source of NO and superoxide. European Journal of Clinical Pharmacology, 2006, 62, 5-12.	0.8	71
70	Nebivolol Inhibits Superoxide Formation by NADPH Oxidase and Endothelial Dysfunction in Angiotensin Il–Treated Rats. Hypertension, 2006, 48, 677-684.	1.3	181
71	Tristetraprolin Regulates the Expression of the Human Inducible Nitric-Oxide Synthase Gene. Molecular Pharmacology, 2005, 67, 2148-2161.	1.0	90
72	Cognitive deficits in aged rats correlate with levels of l-arginine, not with nNOS expression or 3,4-DAP-evoked transmitter release in the frontoparietal cortex. European Neuropsychopharmacology, 2005, 15, 163-175.	0.3	23

#	Article	IF	CITATIONS
73	A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide - Biology and Chemistry, 2005, 12, 97-104.	1.2	164
74	Midostaurin upregulates eNOS gene expression and preserves eNOS function in the microcirculation of the mouse. Nitric Oxide - Biology and Chemistry, 2005, 12, 231-236.	1.2	19
75	Green Tea Inhibits Human Inducible Nitric-Oxide Synthase Expression by Down-Regulating Signal Transducer and Activator of Transcription-11± Activation. Molecular Pharmacology, 2004, 65, 111-120.	1.0	105
76	The Neuronal Nitric Oxide Synthase Is Upregulated in Mouse Skin Repair and in Response to Epidermal Growth Factor in Human HaCaT Keratinocytes. Journal of Investigative Dermatology, 2004, 123, 132-139.	0.3	37
77	Flavonoids from Artichoke (Cynara scolymus L.) Up-Regulate Endothelial-Type Nitric-Oxide Synthase Gene Expression in Human Endothelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 926-932.	1.3	95
78	Cyclic AMP-Mediated Upregulation of the Expression of Neuronal NO Synthase in Human A673 Neuroepithelioma Cells Results in a Decrease in the Level of Bioactive NO Production: Analysis of the Signaling Mechanisms that Are Involvedâ€. Biochemistry, 2004, 43, 7197-7206.	1.2	41
79	Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene. Nitric Oxide - Biology and Chemistry, 2004, 10, 36-41.	1.2	66
80	Red wine increases the expression of human endothelial nitric oxide synthase. Journal of the American College of Cardiology, 2003, 41, 471-478.	1.2	179
81	Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide - Biology and Chemistry, 2003, 9, 95-102.	1.2	110
82	Rho protein-mediated changes in the structure of the actin cytoskeleton regulate human inducible NO synthase gene expression \hat{a}^{-} \uparrow \hat{a}^{-} \uparrow This article contains data from the theses of A.W. and Y.Y Experimental Cell Research, 2003, 287, 106-115.	1.2	41
83	Histamine Upregulates Gene Expression of Endothelial Nitric Oxide Synthase in Human Vascular Endothelial Cells. Circulation, 2003, 107, 2348-2354.	1.6	92
84	Nitric Oxide Increases the Decay of Matrix Metalloproteinase 9 mRNA by Inhibiting the Expression of mRNA-Stabilizing Factor HuR. Molecular and Cellular Biology, 2003, 23, 4901-4916.	1.1	229
85	Transcription of Different Exons 1 of the Human Neuronal Nitric Oxide Synthase Gene Is Dynamically Regulated in a Cell- and Stimulus- Specific Manner. Biological Chemistry, 2003, 384, 351-62.	1.2	29
86	Regulation of the Expression of Inducible Nitric Oxide Synthase. Biological Chemistry, 2003, 384, 1343-64.	1.2	341
87	Sporogen, S14-95, and S-Curvularin, Three Inhibitors of Human Inducible Nitric-Oxide Synthase Expression Isolated from Fungi. Molecular Pharmacology, 2003, 63, 383-391.	1.0	45
88	Anti-Inflammatory Actions of St. John's Wort: Inhibition of Human Inducible Nitric-Oxide Synthase Expression by Down-Regulating Signal Transducer and Activator of Transcription- 11^{\pm} (STAT- 11^{\pm}) Activation. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 254-261.	1.3	88
89	Localization of the two constitutively expressed nitric oxide synthase isoforms (nNOS and eNOS) in the same cell types in the saccule maculae of the frog Rana pipiens by immunoelectron microscopy: evidence for a back-up system?. Journal of Electron Microscopy, 2003, 52, 197-206.	0.9	7
90	Colocalization but differential regulation of neuronal NO synthase and nicotinic acetylcholine receptor in C ₂ C ₁₂ myotubes. American Journal of Physiology - Cell Physiology, 2003, 284, C1065-C1072.	2.1	8

#	Article	IF	Citations
91	NO Synthesis and NOS Regulation. , 2003, , 119-154.		5
92	Resveratrol, a Polyphenolic Phytoalexin Present in Red Wine, Enhances Expression and Activity of Endothelial Nitric Oxide Synthase. Circulation, 2002, 106, 1652-1658.	1.6	605
93	Dual Effect of Ceramide on Human Endothelial Cells. Circulation, 2002, 106, 2250-2256.	1.6	143
94	Revisiting an Old Antimicrobial Drug: Amphotericin B Induces Interleukin-1–Converting Enzyme as the Main Factor for Inducible Nitric-Oxide Synthase Expression in Activated Endothelia. Molecular Pharmacology, 2002, 62, 936-946.	1.0	14
95	Effects of Angiotensin II Infusion on the Expression and Function of NAD(P)H Oxidase and Components of Nitric Oxide/cGMP Signaling. Circulation Research, 2002, 90, E58-65.	2.0	592
96	Inhibitors of Histone Deacetylation Downregulate the Expression of Endothelial Nitric Oxide Synthase and Compromise Endothelial Cell Function in Vasorelaxation and Angiogenesis. Circulation Research, 2002, 91, 837-844.	2.0	200
97	Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide - Biology and Chemistry, 2002, 7, 149-164.	1.2	193
98	Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide - Biology and Chemistry, 2002, 7, 132-147.	1.2	199
99	Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus. Circulation Research, 2001, 88, E14-22.	2.0	941
100	The transport activity of the human cationic amino acid transporter hCAT-1 is downregulated by activation of protein kinase C. British Journal of Pharmacology, 2001, 132, 1193-1200.	2.7	56
101	Differential Distribution of Bradykinin B ₂ Receptors in the Rat and Human Cardiovascular System. Hypertension, 2001, 37, 110-120.	1.3	49
102	Structure-Activity Relationship of Staurosporine Analogs in Regulating Expression of Endothelial Nitric-Oxide Synthase Gene. Molecular Pharmacology, 2000, 57, 427-435.	1.0	46
103	Nitric oxide in the pathogenesis of vascular disease. Journal of Pathology, 2000, 190, 244-254.	2.1	531
104	Amphotericin B severely affects expression and activity of the endothelial constitutive nitric oxide synthase involving altered mRNA stability. British Journal of Pharmacology, 2000, 131, 473-481.	2.7	13
105	Inhibition of small G proteins of the Rho family by statins or Clostridium difficile toxin B enhances cytokine-mediated induction of NO synthase II. British Journal of Pharmacology, 2000, 131, 553-561.	2.7	52
106	Immuno-electron microscopic localization of the $\hat{l}\pm 1$ and \hat{l}^21 -subunits of soluble guanylyl cyclase in the guinea pig organ of Corti. Brain Research, 2000, 885, 6-13.	1.1	20
107	Complex Contribution of the 3′-Untranslated Region to the Expressional Regulation of the Human Inducible Nitric-oxide Synthase Gene. Journal of Biological Chemistry, 2000, 275, 26040-26049.	1.6	160
108	Retinoic Acid Inhibits Nitric Oxide Synthase-2 Expression through the Retinoic Acid Receptor- \hat{l}_{\pm} . Biochemical and Biophysical Research Communications, 2000, 270, 846-851.	1.0	43

#	Article	IF	CITATIONS
109	Regulation of the Expression of Nitric Oxide Synthase Isoforms. , 2000, , 105-128.		20
110	Analysis of NO synthase expression in neuronal, astroglial and fibroblast-like derivatives differen-tiating from PCC7-Mzl embryonic carcinoma cells. European Journal of Cell Biology, 1999, 78, 134-142.	1.6	5
111	NO synthase II in mouse skeletal muscle is associated with caveolin 3. Biochemical Journal, 1999, 340, 723.	1.7	12
112	NO synthase II in mouse skeletal muscle is associated with caveolin 3. Biochemical Journal, 1999, 340, 723-728.	1.7	39
113	Involvement of protein kinases in the induction of NO synthase II in human DLD-1 cells. British Journal of Pharmacology, 1998, 123, 1716-1722.	2.7	36
114	Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-κ B-signaling pathways. British Journal of Pharmacology, 1998, 125, 193-201.	2.7	128
115	Pharmacology of NO:cGMP signal transduction. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 358, 111-112.	1.4	41
116	Inducible nitric oxide synthase in skeletal muscle of patients with chronic heart failure. Journal of the American College of Cardiology, 1998, 32, 964-969.	1.2	57
117	in human heart failure 11During publication process the following related paper has been published by Vejlstrup NG, Bouloumie A, Boesgaard S, Andersen CB, Nielsen-Kudsk JE, Mortensen SA, Kent JD, Harrison DG, Busse R, Alsershvile J. Inducible nitric oxide synthase (iNOS) in the human heart: Expression and localization in congestive heart failure. I Mol Cell Cardiol 1998:30:1215–23 lournal of	1.2	78
118	the American College of Cardiology, 1998, 32, 1179-1186. Neuronal-Type NO Synthase: Transcript Diversity and Expressional Regulation. Nitric Oxide - Biology and Chemistry, 1998, 2, 337-349.	1.2	82
119	Expressional Down-Regulation of Neuronal-Type Nitric Oxide Synthase I by Glucocorticoids in N1E-115 Neuroblastoma Cells. Molecular Pharmacology, 1998, 54, 258-263.	1.0	37
120	Activation of Protein Kinase CÎ \pm and/or Î μ Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene. Molecular Pharmacology, 1998, 53, 630-637.	1.0	145
121	Expressional control of the  constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB Journal, 1998, 12, 773-790.	0.2	558
122	Coexpression of inducible NO synthase and soluble guanylyl cyclase in colonic enterocytes: a pathophysiologic signaling pathway for the initiation of diarrhea by gramâ€negative bacteria?. FASEB Journal, 1998, 12, 1643-1649.	0.2	19
123	Human Cationic Amino Acid Transporters hCAT-1, hCAT-2A, and hCAT-2B: Three Related Carriers with Distinct Transport Propertiesâ€,‡. Biochemistry, 1997, 36, 6462-6468.	1.2	137
124	Expressional downregulation of neuronal-type NO synthase I in guinea pig skeletal muscle in response to bacterial lipopolysaccharide. FEBS Letters, 1997, 410, 319-323.	1.3	23
125	Characterization of nitric oxide synthase isoforms expressed in different structures of the guinea pig cochlea. Brain Research, 1997, 747, 26-33.	1.1	66
126	Identification of the NO Synthase isoforms Expressed in Human Neutrophil Granulocytes, Megakaryocytes and Platelets. Thrombosis and Haemostasis, 1997, 77, 163-167.	1.8	139

#	Article	IF	CITATIONS
127	Inducible NO synthase II and neuronal NO synthase I are constitutively expressed in different structures of guinea pig skeletal muscle: implications for contractile function. FASEB Journal, 1996, 10, 1614-1620.	0.2	133
128	Immunohistochemical localization of nitric oxide synthases. Methods in Enzymology, 1996, 268, 510-515.	0.4	11
129	Purification of isoforms of nitric oxide synthase. Methods in Enzymology, 1996, 268, 334-339.	0.4	15
130	In Murine 3T3 Fibroblasts, Different Second Messenger Pathways Resulting in the Induction of NO Synthase II (iNOS) Converge in the Activation of Transcription Factor NF-ÎB. Journal of Biological Chemistry, 1996, 271, 6039-6044.	1.6	113
131	Nitric oxide synthase isozymes antibodies. The Histochemical Journal, 1995, 27, 738-744.	0.6	47
132	Expression and Expressional Control of Nitric Oxide Synthases in Various Cell Types. Advances in Pharmacology, 1995, 34, 171-186.	1.2	83
133	Isoforms of nitric oxide synthase. Biochemical Pharmacology, 1995, 50, 1321-1332.	2.0	353
134	Nitric oxide synthase isozymes antibodies. The Histochemical Journal, 1995, 27, 738-744.	0.6	2
135	Ontogeny of nitric oxide synthase in the lumbosacral spinal cord of the neonatal rat. Developmental Brain Research, 1994, 81, 201-217.	2.1	32
136	Differential distribution of nitric oxide synthase in neural pathways to the urogenital organs (urethra, penis, urinary bladder) of the rat. Brain Research, 1994, 646, 279-291.	1.1	152
137	Upregulation of neuronal nitric oxide synthase and mRNA, and selective sparing of nitric oxide synthase-containing neurons after local cerebral ischemia in rat. Brain Research, 1994, 654, 85-95.	1.1	201
138	[26] Isoforms of nitric-oxide synthase: Purification and regulation. Methods in Enzymology, 1994, 233, 258-264.	0.4	34
139	Nitric Oxide Synthase in Bovine Superior Cervical Ganglion. Journal of Neurochemistry, 1993, 61, 1120-1126.	2.1	59
140	Nitric oxide synthases in the cardiovascular system. Trends in Cardiovascular Medicine, 1993, 3, 104-110.	2.3	48
141	Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Letters, 1993, 316, 175-180.	1.3	483
142	A correlation between soluble brain nitric oxide synthase and NADPH-diaphorase activity is only seen after exposure of the tissue to fixative. Neuroscience Letters, 1993, 155, 61-64.	1.0	474
143	Developmental changes of cytosolic and particulate nitric oxide synthase in rat brain. Developmental Brain Research, 1993, 73, 199-203.	2.1	88
144	Particulate Endothelial Nitric Oxide Synthase: Requirement and Content of Tetrahydrobiopterin, FAD, and FMN. Endothelium: Journal of Endothelial Cell Research, 1993, 1, 147-152.	1.7	17

#	Article	IF	Citations
145	Particulate and Soluble Bovine Endothelial Nitric Oxide Synthases Are Structurally Similar Proteins Yet Different from Soluble Brain Nitric Oxide Synthase. Journal of Cardiovascular Pharmacology, 1992, 20, S50-S53.	0.8	13
146	Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA. British Journal of Pharmacology, 1992, 106, 948-952.	2.7	27
147	Nitric oxide synthase in ferret brain: localization and characterization. British Journal of Pharmacology, 1992, 107, 849-852.	2.7	9
148	Bioassay for EDRF/NO by accumulation of cyclic GMP in RFL-6 fetal rat lung fibroblasts. Methods, 1992, 1, 117-123.	0.5	1
149	Endothelial nitric oxide synthase is myristylated. FEBS Letters, 1992, 309, 402-404.	1.3	86
150	Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: inhibition by transforming growth factor-ĀŸ. European Journal of Pharmacology, 1992, 225, 161-165.	2.7	76
151	Phosphorylation by calcium calmodulin-dependent protein kinase II and protein kinase C modulates the activity of nitric oxide synthase. Biochemical and Biophysical Research Communications, 1991, 180, 1396-1402.	1.0	267
152	Characterization of nitric oxide synthases in nonâ€adrenergic nonâ€cholinergic nerve containing tissue from the rat anococcygeus muscle. British Journal of Pharmacology, 1991, 104, 289-291.	2.7	99
153	Endothelial cells have a particulate enzyme system responsible for EDRF formation: Measurement by vascular relaxation. Biochemical and Biophysical Research Communications, 1991, 176, 1417-1423.	1.0	45
154	Glyceryl trinatrate increases platelet cyclic GMP after metabolism in fibroblasts. European Journal of Pharmacology, 1991, 200, 175-178.	1.7	9
155	lsoforms of nitric oxide synthase Characterization and purification from different cell types. Biochemical Pharmacology, 1991, 42, 1849-1857.	2.0	813
156	Platelets, Endothelium-Dependent Responses and Atherosclerosis. Annals of Medicine, 1991, 23, 545-550.	1.5	11
157	Production of an EDRFâ€like activity in the cytosol of N1Eâ€115 neuroblastoma cells. FASEB Journal, 1990, 4, 1494-1500.	0.2	38
158	Regional distribution of EDRF/NO-synthesizing enzyme(s) in rat brain. Biochemical and Biophysical Research Communications, 1990, 168, 727-732.	1.0	240
159	Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP. European Journal of Pharmacology, 1989, 164, 103-110.	1.7	51
160	Ciclosporin A inhibits endothelium-dependent vasodilatation and vascular prostacyclin production. European Journal of Pharmacology, 1989, 165, 165-169.	1.7	79
161	Gossypol attenuates selectively the blood pressure lowering effect of endothelium-dependent vasodilators in the rabbit in vivo. European Journal of Pharmacology, 1988, 145, 217-221.	1.7	15
162	Mechanisms of action of lipoxygenase and cytochrome Pâ€450â€monoâ€oxygenase inhibitors in blocking endotheliumâ€dependent vasodilatation. British Journal of Pharmacology, 1988, 93, 569-578.	2.7	50

#	Article	IF	CITATIONS
163	Decreased systemic formation of prostaglandin E and prostacyclin, and unchanged thromboxane formation, in alcoholics during withdrawal as estimated from metabolites in urine. Clinical Science, 1987, 73, 277-283.	1.8	9
164	Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thrombosis Research, 1987, 47, 561-571.	0.8	161
165	Selective inhibition by gossypol of endotheliumâ€dependent relaxations augments relaxations to glyceryl trinitrate in rabbit coeliac artery. British Journal of Pharmacology, 1987, 92, 237-240.	2.7	41
166	Endothelium-dependent relaxation of human epicardial coronary arteries: frequent lack of effect of acetylcholine. European Journal of Pharmacology, 1986, 128, 277-281.	1.7	47
167	The role of endothelial and nonâ€endothelial prostaglandins in the relaxation of isolated blood vessels of the rabbit induced by acetylcholine and bradykinin. British Journal of Pharmacology, 1986, 87, 521-532.	2.7	74
168	Properties and Mechanisms of Production and Action of Endothelium-Derived Relaxing Factor. Journal of Cardiovascular Pharmacology, 1986, 8, S45-51.	0.8	31
169	Studies on the mechanism of central cardiovascular and temperature responses to prostaglandin D2. Prostaglandins, Leukotrienes, and Medicine, 1985, 18, 301-308.	0.8	12
170	Hypoxia enhances prostaglandin synthesis in renal mesangial cell cultures. Prostaglandins, 1985, 30, 109-118.	1.2	23
171	Species-dependent differences in the nature of endothelium-derived vascular relaxing factor. European Journal of Pharmacology, 1984, 106, 639-643.	1.7	107
172	The endothelium-dependent vasodilator effect of acetylcholine: Characterization of the endothelial relaxing factor with inhibitors of arachidonic acid metabolism. European Journal of Pharmacology, 1984, 103, 65-70.	1.7	69
173	The role of the kidney in the metabolism of prostacyclin by the 15-hydroxyprostaglandin dehydrogenase pathway in vivo. Lipids and Lipid Metabolism, 1984, 793, 338-345.	2.6	2
174	Effects of intracerebroventricular administration of prostaglandin D2 on behaviour, blood pressure and body temperature as compared to prostaglandins E2 and F2?. Psychopharmacology, 1983, 80, 365-370.	1.5	53
175	Potential anticonvulsive properties of endogenous prostaglandins formed in mouse brain. Brain Research, 1982, 240, 303-310.	1.1	92
176	Rapid and effective conversion of 6-keto-prostaglandin F1 \hat{l} ± to 6,15-diketo-13,14-dihydro-prostaglandin F1 \hat{l} ±-immunoreactive material in vivo. Prostaglandins, Leukotrienes, and Medicine, 1982, 9, 277-284.	0.8	2
177	Formation and elimination of prostacyclin metabolites in the cat in vivo as determined by radioimmunoassay of unextracted plasma. European Journal of Pharmacology, 1981, 74, 19-26.	1.7	27